Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avalglucosidase Alfa in Non-classic Pompe Disease
NCT07652814Phase 4Active, not recruiting
- Sponsor
- Iris Pharma
- Start
- Oct 2022
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of avalglucosidase alfa in Pompe disease, sponsored by Iris Pharma. Primary endpoints: Incidence/occurrence of adverse events at 5 years, Occurrence of antibodies against avalglucosidase alfa at 5 years and 13 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
avalglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT07652814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652814.